330 related articles for article (PubMed ID: 26750639)
1. Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.
Xiao Y; Muser E; Fu DJ; Lafeuille MH; Pilon D; Emond B; Wu A; Duh MS; Lefebvre P
Curr Med Res Opin; 2016; 32(4):759-69. PubMed ID: 26750639
[TBL] [Abstract][Full Text] [Related]
2. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
[TBL] [Abstract][Full Text] [Related]
3. Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophrenia.
Pilon D; Muser E; Lefebvre P; Kamstra R; Emond B; Joshi K
BMC Psychiatry; 2017 Jun; 17(1):207. PubMed ID: 28576133
[TBL] [Abstract][Full Text] [Related]
4. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
[TBL] [Abstract][Full Text] [Related]
5. A comparison of treatment patterns, healthcare resource utilization, and costs among young adult Medicaid beneficiaries with schizophrenia treated with paliperidone palmitate or oral atypical antipsychotics in the US.
Manjelievskaia J; Amos TB; El Khoury AC; Vlahiotis A; Cole A; Juneau P
J Med Econ; 2018 Dec; 21(12):1221-1229. PubMed ID: 30238806
[TBL] [Abstract][Full Text] [Related]
6. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
Joshi K; Lafeuille MH; Kamstra R; Tiggelaar S; Lefebvre P; Kim E; Yue Y; Tandon N
J Comp Eff Res; 2018 Feb; 7(2):121-133. PubMed ID: 28809128
[TBL] [Abstract][Full Text] [Related]
7. Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.
Xiao Y; Muser E; Lafeuille MH; Pesa J; Fastenau J; Duh MS; Lefebvre P
J Comp Eff Res; 2015 Nov; 4(6):579-92. PubMed ID: 26168935
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.
Kamstra R; Pilon D; Lefebvre P; Emond B; Joshi K
Curr Med Res Opin; 2018 Aug; 34(8):1377-1388. PubMed ID: 29452492
[TBL] [Abstract][Full Text] [Related]
9. Projecting the Long-Term Economic Impact of Once-Monthly Paliperidone Palmitate Versus Oral Atypical Antipsychotics in Medicaid Patients with Schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Llaneza A; Kim E; Lefebvre P
J Manag Care Spec Pharm; 2020 Feb; 26(2):176-185. PubMed ID: 32011960
[TBL] [Abstract][Full Text] [Related]
10. The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.
El Khoury AC; Pilon D; Morrison L; Shak N; Vermette-Laforme M; Amos TB; Kim E; Lefebvre P
Curr Med Res Opin; 2019 Mar; 35(3):395-405. PubMed ID: 30526125
[TBL] [Abstract][Full Text] [Related]
11. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.
Young-Xu Y; Duh MS; Muser E; DerSarkissian M; Faust E; Kageleiry A; Bhak RH; Fu DJ; Lefebvre P; Shiner B
J Clin Psychiatry; 2016 Oct; 77(10):e1332-e1341. PubMed ID: 27574835
[TBL] [Abstract][Full Text] [Related]
12. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
Baser O; Xie L; Pesa J; Durkin M
J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization of second-generation long-acting injectable antipsychotics in schizophrenia: risperidone versus paliperidone palmitate.
Joshi K; Pan X; Wang R; Yang E; Benson C
Curr Med Res Opin; 2016 Nov; 32(11):1873-1881. PubMed ID: 27479694
[TBL] [Abstract][Full Text] [Related]
14. Health care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.
Pesa JA; Doshi D; Wang L; Yuce H; Baser O
Curr Med Res Opin; 2017 Apr; 33(4):723-731. PubMed ID: 28044455
[TBL] [Abstract][Full Text] [Related]
15. Antipsychotic Adherence, Resource Use, and Costs Before and After the Initiation of Once-monthly Paliperidone Palmitate Therapy Among Medicaid Beneficiaries With Prior Schizophrenia Relapse.
Zhdanava M; Lin D; Lafeuille MH; Ghelerter I; Morrison L; Lefebvre P; Joshi K
Clin Ther; 2021 Mar; 43(3):535-548. PubMed ID: 33589216
[TBL] [Abstract][Full Text] [Related]
16. Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Yan T; Greene M; Chang E; Houle CR; Waters HC; Tarbox MH; Broder MS
Clin Ther; 2020 Jan; 42(1):77-93. PubMed ID: 31928831
[TBL] [Abstract][Full Text] [Related]
17. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population.
Joshi K; Muser E; Xu Y; Schwab P; Datar M; Suehs B
J Comp Eff Res; 2018 Aug; 7(8):723-735. PubMed ID: 29722547
[No Abstract] [Full Text] [Related]
18. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
19. Risk of subsequent relapses and corresponding healthcare costs among recently-relapsed Medicaid patients with schizophrenia: a real-world retrospective cohort study.
Patel C; Emond B; Morrison L; Lafeuille MH; Lefebvre P; Lin D; Kim E; Joshi K
Curr Med Res Opin; 2021 Apr; 37(4):665-674. PubMed ID: 33507831
[TBL] [Abstract][Full Text] [Related]
20. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
